Orphan designation: oregovomab Treatment of ovarian cancer, 30/07/2002 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 12:06
Orphan designation: oregovomab Treatment of ovarian cancer, 30/07/2002 Withdrawn
Orphan designation: zilucoplan Treatment of myasthenia gravis, 18/07/2022 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 12:06
Orphan designation: zilucoplan Treatment of myasthenia gravis, 18/07/2022 Withdrawn
Amended Biologics Working Party Vaccines Quality Operational Expert Group (BV-OEG) Influenza Meeting: EU recommendations for the seasonal influenza vaccine composition for the season 2026/2027
Submitted by Anonymous (not verified) on 26 May 2026 - 12:05
Amended Biologics Working Party Vaccines Quality Operational Expert Group (BV-OEG) Influenza Meeting: EU recommendations for the seasonal influenza vaccine composition for the season 2026/2027
Orphan designation: macitentan Treatment of idiopathic pulmonary fibrosis, 28/01/2010 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 12:03
Orphan designation: macitentan Treatment of idiopathic pulmonary fibrosis, 28/01/2010 Withdrawn
Orphan designation: macitentan Treatment of functional single ventricle congenital heart disease, 20/05/2021 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 12:00
Orphan designation: macitentan Treatment of functional single ventricle congenital heart disease, 20/05/2021 Withdrawn
Orphan designation: macitentan Treatment of chronic thromboembolic pulmonary hypertension, 10/12/2021 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 12:00
Orphan designation: macitentan Treatment of chronic thromboembolic pulmonary hypertension, 10/12/2021 Withdrawn
Orphan designation: Mavoglurant Treatment of fragile X syndrome, 10/10/2012 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 11:58
Orphan designation: Mavoglurant Treatment of fragile X syndrome, 10/10/2012 Withdrawn
Orphan designation: humanised IgG2k Fc-modified bispecific monoclonal antibody against CD3 and BCMA Treatment of multiple myeloma, 19/07/2021 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 11:56
Orphan designation: humanised IgG2k Fc-modified bispecific monoclonal antibody against CD3 and BCMA Treatment of multiple myeloma, 19/07/2021 Withdrawn
Orphan designation: vutrisiran Treatment of Stargardt's disease, 10/08/2022 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 11:56
Orphan designation: vutrisiran Treatment of Stargardt's disease, 10/08/2022 Withdrawn
Orphan designation: cedazuridine,decitabine Treatment of myelodysplastic syndromes, 16/08/2023 Withdrawn
Submitted by Anonymous (not verified) on 26 May 2026 - 11:55
Orphan designation: cedazuridine,decitabine Treatment of myelodysplastic syndromes, 16/08/2023 Withdrawn